News

T-E Meds supported YmmunoBio in the development of an MMAF/Exatecan dual-payload ADC, which was recently incorporated into a novel ADC […]

T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the

T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future

T-E Pharma announced that its subsidiary, T-E Meds, Inc., has been shortlisted for the prestigious “Best New Drug Developer” category

On June 24, 2025, T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning

Dr. Tse-Wen Chang, founder and chairman of Immunwork and T-E Meds, shared the latest developments of both companies on 15th

We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to

Immunwork with its “Application of an Innovative Fatty Acid Bundle Platform in the Development of Ultra-Long-Acting Drugs” project, has been

The founder of Immunwork and T-E Meds, Dr. Tse-Wen Chang, shared the latest developments of the two companies on 11th